Contrave generic
Contrave is an anti-obesity drug owned by Nalpropion Pharmaceuticals. The active ingredients Bupropion Hydrochloride and Naltrexone Hydrochloride contribute to its effectiveness. It was first authorized for market use on September 10, 2014 and has a total of 20 patents.
When will Contrave generic be available?
The generic version of Contrave is not expected to be available until after July 2, 2034. This includes a series of patents with the last one, titled 'Compositions and methods for weight loss in at-risk patient populations,' expiring on July 2, 2034.
Contrave uses
Contrave is primarily used for chronic weight management and treating overweight or obesity. The combination of Naltrexone and Bupropion in a layered formulation contributes to weight loss, an escalating dose schedule, and can impact blood glucose parameters in patients with insulin resistance. It is also beneficial for overweight or obese patients with major depressive disorder.
Contrave patent expiration
Contrave has a strong patent portfolio with 20 in total. The last patent, 'Compositions and methods for weight loss in at-risk patient populations,' is set to expire on July 2, 2034, thus the prospect for Contrave generics is not until after that date. Below are the details of the patent: